T-NHL subtypes and clinical perspective

2007 PROGRAM GRANT - (IMMUNE REGULATION, EFFECTOR FUNCTION AND HUMAN IMMUNOTHERAPY)

The immune system plays an important role in protecting the host from viral and bacterial infections, and inhibits cancer onset and progress..

2007 PROGRAM GRANT - (IMMUNE REGULATION, EFFECTOR FUNCTION AND HUMAN IMMUNOTHERAPY)

The immune system plays an important role in protecting the host from viral and bacterial infections, and inhibits cancer onset and progress..

DISCOVERY OF NEW TREATMENTS FOR THERAPY-RESISTANT MULTIPLE MYELOMA.

EPIGENETICS AND CANCER THERAPY

IDENTIFYING AND TARGETING MYELOMA STEM CELLS IN A NOVEL MOUSE MODEL AND IN HUMANS

IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY

We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells..

IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY

We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells..

IMMUNOBIOLOGY AND IMMUNOTHERAPY OF CANCER

For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 year..

PHASE 1 STUDY FOR INFUSION OF AUTOLOGOUS PERIFERAL BLOOD T LYMPHOCYTES TRANDUSCED WITH AN ANTI LEWIS Y CHIMERIC RECEPTOR GENE IN PATIENTS WITH LEWIS Y POSITIVE MULTIPLE MYELOMA

TARGETING EPIGENETIC ENZYMES IN CORE BINDING FACTOR AML

Acute myeloid leukemia (AML) is a devastating disease and there are ~900 new cases diagnosed annually in Australia. A subset of AML, called ..

VICTORIAN EPIGENETICS GROUP (VEG): A COLLABORATION FOR PERSONALISED EPIGENETIC CANCER THERAPY THROUGH PRE-CLINICAL EVALUATION, NOVEL BIOMARKER DEVELOPMENT AND EARLY PHASE CLINICAL TRIALS OF NEW DRUGS.